| Date | Title | Description | |
|---|---|---|---|
| 21 Feb 2023 | Annual Corporate Governance Report | ROVI releases the 2022 Annual Corporate Governance Report | Download |
| 21 Feb 2023 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors | Download |
| 16 Feb 2023 | On business and financial situation | The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States. | Download |
| 09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
| 15 Dec 2022 | On Corporate Governance | The Company informs about changes in the Board of Directors and the creation of an Advisory Committee. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 31 Jan 2020 | R&D: new licenses, patents and registered trademarks | The Company informs about the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union | Download |
| 08 Jan 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2019 | Download |
| 20 Dec 2019 | Composition of the board of directors | The Company informs about the composition of its Board of Directors and its Audit and Appointments and Remuneration Committees. | Download |
| 24 Nov 2019 | Strategic plans, profit forecasts and presentations | The Company releases the presentation related to its strategy update because of the 2019 Investor Day. | Download |
| 07 Nov 2019 | Information on P&L | ROVI releases the press release related to the first nine months 2019 financial results | Download |